By Katherine Hamilton
Repare Therapeutics plans to find a partner before moving forward with developing a possible treatment for cancer as it aims to extend its cash runway into 2027.
The oncology company said Thursday it will find a partner before it proceeds with planned and regulatory-supported pivotal development of lunresertib and camonsertib, which together are meant to treat gynecological cancer.
Repare is also reorganizing its resources and clinical portfolio to focus on advancing the Phase 1 clinical programs of its tumor treatments RP-1664 and RP-3467.
Savings from late-stage clinical funding and planned layoffs are expected to extend the company's cash runway into the mid-2027, the company said.
In August, Repare said it planned to cut about a quarter of its workforce as part of strategic move to refocus efforts on its lunresertib, camonsertib, RP-1664 and RP-3467 products. It anticipated the layoffs will generate about $15 million in annual savings.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 09, 2025 17:00 ET (22:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。